Logo image of ONCS

OncoSec Medical Incorporated (ONCS) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:ONCS - US68234L4059 - Common Stock

0.2772 USD
+0.07 (+31.87%)
Last: 6/23/2023, 8:00:02 PM
0.23 USD
-0.05 (-17.03%)
After Hours: 6/23/2023, 8:00:02 PM
Buy % Consensus

43

ChartMill assigns a Buy % Consensus number of 43% to ONCS. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 5.1. This target is 1739.83% above the current price.
ONCS was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about ONCS.
In the previous month the buy percentage consensus was at a similar level.
ONCS was analyzed by 6 analysts. More opinions would make the average more meaningful.

Related screens

ONCS Historical Analyst RatingsONCS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -76 -69 -62 -55 -48 -41 -34 -27 -20 -13 -6 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.285.055.105.105.25 - 1,721.79% 1,739.83% 1,739.83% 1,793.94%

Related screens

ONCS Current Analyst RatingONCS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2022-11-14 BTIG Downgrade Buy -> Neutral
2021-03-08 BTIG Initiate Buy

OncoSec Medical Incorporated / ONCS FAQ

What is the price target for ONCS stock?

6 analysts have analysed ONCS and the average price target is 5.1 USD. This implies a price increase of 1739.83% is expected in the next year compared to the current price of 0.2772.


How do analysts rate OncoSec Medical Incorporated (ONCS)?

The consensus rating for OncoSec Medical Incorporated (ONCS) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.